Humanized monoclonals and other biological initiatives.
Halloran
P F
PF
Department of Medicine, University of Alberta, Edmonton, Canada. phil.halloran@ualberta.ca
Prommool
S
S
D000069594:Abatacept; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D015703:Antigens, CD; D000943:Antigens, Differentiation / Q000627:therapeutic use; D060908:CTLA-4 Antigen; D006801:Humans; D018796:Immunoconjugates; D007165:Immunosuppression Therapy / Q000379:methods*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015375:Receptors, Interleukin-2 / Q000276:immunology; D011994:Recombinant Proteins / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000276:immunology
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000943:Antigens, Differentiation; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D018796:Immunoconjugates; D007166:Immunosuppressive Agents; D015375:Receptors, Interleukin-2; D011994:Recombinant Proteins; D000069594:Abatacept